News
PBM
5.67
+1.89%
0.11
Psyence BioMed Stock Rises On Exclusive U.S. Ibogaine License Deal
NASDAQ · 13h ago
Psyence Biomedical announces exclusive U.S. Ibogaine license for TIRC
TipRanks · 14h ago
Psyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S.
Benzinga · 14h ago
Weekly Report: what happened at PBM last week (0921-0925)?
Weekly Report · 15h ago
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Barchart · 19h ago
Psychedelic: Optimi completes psilocybin production for Phase 2 trial
TipRanks · 4d ago
Psyence BioMed Plans $5 Mln Cash Investment In PsyLabs For U.S. Ibogaine Program
NASDAQ · 5d ago
Psyence Biomedical Launches Texas Ibogaine Unit and Commits Up to US$5 Million in PsyLabs
TipRanks · 5d ago
Psyence Biomedical announces strategic Ibogaine investment
TipRanks · 5d ago
Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs
Benzinga · 5d ago
Press Release: Psyence BioMed Announces Strategic -2-
Dow Jones · 5d ago
Weekly Report: what happened at PBM last week (0914-0918)?
Weekly Report · 09/21 10:17
Psychedelic: Definium’s LSD-based drug meets endpoints in GAD study
TipRanks · 09/17 13:55
Psyence BioMed Establishes Texas Entity To Advance U.S. Ibogaine Development
NASDAQ · 09/14 12:28
Psyence BioMed Launches Texas Ibogaine Research Unit to Drive U.S. Neuroplastogen Development
TipRanks · 09/14 11:58
Psyence Biomedical establishes Texas Ibogaine Research Corporation
TipRanks · 09/14 11:10
Weekly Report: what happened at PBM last week (0907-0911)?
Weekly Report · 09/14 10:22
Weekly Report: what happened at PBM last week (0831-0904)?
Weekly Report · 09/07 10:15
Weekly Report: what happened at PBM last week (0824-0828)?
Weekly Report · 08/31 10:23
Psyence Biomedical files to sell 1.15M common shares for holders
TipRanks · 08/26 10:10
More
Webull provides a variety of real-time PBM stock news. You can receive the latest news about Psyence Biomedical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.